Jyong Biotech (NASDAQ:MENS) Sets New 12-Month High - What's Next?

Key Points

• Jyong Biotech Ltd. shares reached a new 52-week high of $64.54 during trading, up from the previous close of $55.13, with a trading volume of 347,441 shares.
• Wall Street Zen has upgraded Jyong Biotech to a "hold" rating as of June 30th, signaling a more neutral stance on the stock.
• The company's 50-day moving average is noted at $31.17, indicating a significant recent increase in share price performance.

Shares of Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $64.54 and last traded at $64.42, with a volume of 347441 shares traded. The stock had previously closed at $55.13.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.

Jyong Biotech Trading Up 16.9%

The company's 50-day moving average is $31.17.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.